Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 12, 2016

Aspen to acquire commercialisation rights for AstraZeneca’s anaesthetics outside US

Aspen Global has entered into a commercialisation agreement with UK-based pharmaceutical company AstraZeneca, to acquire the commercialisation rights for the latter’s global portfolio of anaesthetic medicines outside the US.

By Lopamudra Roy

Aspen Global has entered into a commercialisation agreement with UK-based pharmaceutical company AstraZeneca, to acquire the commercialisation rights for the latter’s global portfolio of anaesthetic medicines outside the US.

The agreement includes seven anaesthetic medicines, EMLA (topical anaesthetic), Diprivan (general anaesthesia), and five local anaesthetics including Xylocaine / Xylocard / Xyloproct, Naropin, Marcaine, Carbocaine and Citanest.

AstraZeneca CEO Pascal Soriot said: "AstraZeneca has a rich heritage in anaesthetic medicines and this agreement will extend the reach of our established portfolio to a greater number of patients through AGI’s extensive commercial network."

Under the deal, the acquisition will be completed for an upfront consideration of $520m, in addition to which Aspen Global will pay up to $250m to AstraZeneca in a product sales-related payment, as well as double-digit percentage trademark royalties on Product Sales.

"This is a strategically-important investment for AGI and it is pleasing to have a company such as AstraZeneca recognise Aspen’s commercial competencies."

With the acquisition, AstraZeneca will be responsible for producing and delivering the products on a cost plus basis to Aspen Global for an initial period of ten years.

Upon completion of the deal, Aspen will carry out the responsibilities for all activities related to the sale of its anaesthetics portfolio in all relevant markets.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Aspen group chief executive Stephen Saad said: "This is a strategically-important investment for AGI and it is pleasing to have a company such as AstraZeneca recognise Aspen’s commercial competencies."

AstraZeneca’s portfolio of anaesthetic medicines is available in more than a hundred countries across the world, including major markets such as Japan, China, Brazil and Australia.

In 2006, the commercialisation rights of the anaesthetic portfolio in the US markets were sold to Abraxis, which is now part of European health care company Fresenius Kabi.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU